1 completed, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow HDT Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321 - Vaccine, Crimean-Congo Hemorrhagic Fever | Phase 1 | Recruiting | HDT Bio | 48 | 2025-07-10 | 2025-07-28 |
| Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein HDT-301 - SARS-CoV2 Infection | Phase 1 | Completed | HDT Bio | 48 | 2022-01-24 | 2024-10-23 |
COVID-19 (1) · Hemorrhagic Fever, Crimean (1)
United States (2)
Malcolm Duthie, PhD (1) · Steven G Reed, Ph.D (1)